Monoclonal antibodies (mAbs) are increasingly used to treat rheumatoid arthritis (RA). At
present, anti-tumor necrosis factor-α drugs (infliximab, adalimumab, certolizumab pegol, and …

More than 20 monoclonal antibodies have been approved as therapeutic drugs by the US
Food and Drug Administration, and it is quite likely that the number of approved antibodies …

Monoclonal antibodies (mAbs) have complex pharmacology; pharmacokinetics and
pharmacodynamics depend on mAb structure and target antigen. mAbs targeting soluble …

Aims This study aimed at describing adalimumab pharmacokinetics (PK) and the
concentration–effect relationship of adalimumab using pharmacokinetic–pharmacodynamic …

The pharmacokinetics of monoclonal antibodies is highly variable among patients. Several
factors of variability, referred to as covariates in pharmacokinetic modeling, are known to …

Monoclonal antibodies (MAbs) exhibit complex pharmacokinetics (PK) and
pharmacodynamics (PD, response) against tumor necrosis factor (TNF). Many factors impact …

Introduction: The number of monoclonal antibodies available for clinical use and under
development has dramatically increased in the last 10 years. Understanding their …

Background: Because traditional therapies for rheumatoid arthritis (RA) such as
methotrexate (MTX) do not produce an adequate response in many patients, newer …

A growing number of population pharmacokinetic analyses of therapeutic monoclonal
antibodies (mAbs) have been published in the scientific literature. The aims of this article are …

Aims Pharmacokinetic (PK) similarity was assessed among PF‐05280586 (a proposed
biosimilar) vs. rituximab sourced from the European Union (rituximab‐EU) and the United …